Ankylosing Spondylitis
Conditions
Brief summary
Forty-five AS patients and 35 healthy controls were enrolled in this study. Patients diagnosed with AS according to Modified New York criteria were included in the study. Clinical and laboratory measurements, duration of symptoms, age and body mass index (BMI) of AS patients were performed and compared with age and BMI matched control group.
Detailed description
Detailed histories of all participants were obtained, and systemic and rheumatologic examinations were performed. We excluded all participants who had a history of hyperlipidemia, liver, renal, hematological, familial thyroid, neoplastic, autoimmune infectious diseases and receiving anti-inflammatory drugs. We measured serum galectin-3 levels using a commercial chemiluminescent microparticle immunoassay. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to assess disease activity in AS patients.
Interventions
OTHERSerum galectin-3 concentration was measured.
Serum galectin-3 concentration was measured using a commercial chemiluminescent microparticle immunoassay.
Sponsors
Recep Tayyip Erdogan University Training and Research Hospital
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Ankylosing spondylitis patients * Healthy controls
Exclusion criteria
* Hyperlipidemia * Liver diseases * Renal diseases * Hematological diseases * Familial thyroid diseases * Neoplastic diseases * Autoimmune infectious diseases * Receiving anti-inflammatory drugs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Relationship Between Galectin-3 Level and Disease Activity in Ankylosing Spondylitis Patients | 5 months | Correlation |
Outcome results
None listed